IP trouble defers launch of Novo's long-acting hemophilia therapy

Long-acting hemophilia therapy Eseproct has won FDA approval, but US patients will have to wait until next year to access it, in a blow for maker Novo Nordisk which is looking to stave off Roche’s recently launched rival therapy Hemlibra.